MedTrace Logo

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

NCT05068752 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-30

Study results available
· View outcomes & findings →

Summary

The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.

Conditions

  • Pancreas Cancer

Interventions

DRUG

Vemurafenib

Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID

DRUG

Sorafenib

Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Genentech, Inc.

    collaborator INDUSTRY

  • HonorHealth Research Institute

    lead OTHER

Principal Investigators

  • Erkut Borazanci, MD, MS · HonorHealth Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-28
Primary Completion
2024-11-08
Completion
2024-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05068752 on ClinicalTrials.gov